Table 1.
Patient and graft characteristics
| Demographics | Related (n = 78) | Unrelated (n = 39) | Total (n = 117) |
|---|---|---|---|
| Median age, y (range) | 48 (21-66) | 52 (22-66) | 50 (21-66) |
| Female sex, no. (%) | 35 (45) | 23 (59) | 58 (50) |
| Disease, no. | |||
| De novo AML* | 20 | 13 | 33 |
| CR1*/CR ≥ 2 | 5/4 | 5/4 | 10/8 |
| Not in CR | 11 | 4 | 15 |
| Secondary AML | 16 | 9 | 25 |
| CR1*/CR ≥ 2 | 8/1 | 7/1 | 15/2 |
| Not in CR | 7 | 1 | 8 |
| MDS | 6 | 8 | 14 |
| Secondary | 3 | 3 | 6 |
| Not in CR | 5 | 8 | 13 |
| ALL† | 7 | 3 | 10 |
| Not in CR | 1 | 0 | 1 |
| CML | 3 | 5 | 8 |
| Accelerated phase/active disease | 1 | 1 | 2 |
| Chronic phase/active disease | 1 | 4 | 5 |
| Chronic phase in CR2 | 1 | 0 | 1 |
| CLL, all refractory | 2 | 1 | 3 |
| Multiple myeloma | 5 | 0 | 5 |
| Not in CR | 4 | 0 | 4 |
| NHL | 8 | 0 | 8 |
| Not in CR | 6 | 0 | 6 |
| Hodgkin lymphoma | 11 | 0 | 11 |
| Not in CR | 11 | 0 | 11 |
| Cytomegalovirus serology‡ | |||
| CMV D−R− | 27 | 12 | 39 |
| CMV D+R− | 15 | 5 | 20 |
| CMV D+R+ | 16 | 5 | 21 |
| CMV D−R+ | 18 | 17 | 35 |
| Donor/recipient sex, no.‡ | |||
| Female → male | 21 | 4 | 25 |
| Other | 57 | 34 | 91 |
| Infused cell doses, median (IQR) | |||
| Total nucleated cells, × 108/kg | 4.1 (3.4-4.8) | 4.0 (3.0-4.7) | 4.1 (3.2-4.7) |
| CD34+ cells, × 106/kg | 3.6 (2.8-4.8) | 3.9 (2.8-5.5) | 3.7 (2.8-4.9) |
IQR indicates interquartile range.
*
A total of 10 patients with de novo AML were in CR1 (5 unrelated, 5 related) with following high-risk disease: Flt-3+ mutation (4), monosomy 7 (1), more than 3 cytogenetic abnormalities (1), t(11;19) (1), t(9;11) plus trisomy 8 and leukemia cutis (1), primary refractory but with CR following reinduction (1), and morphologic CR with aberrant blast phenotype by flow cytometry (1).
†
A total of 7 patients with ALL who underwent transplantation in CR1 had high-risk disease: Ph+ ALL (4), t(4;11) (1), natural killer ALL (1), T-cell lymphoblastic lymphoma (1).
‡
Data are available for 115 donor/recipient pairs.